There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition.
A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
The lab and its patients were formerly served by Providence Saint Joseph Medical Center.
Quidel's CEO said that the strategic acquisition adds an extensive cardiovascular and toxicology POC offering to the firm's medical diagnostics portfolio.
Investment banks Canaccord Genuity and Raymond James also raised their price targets on the company.
Quidel said that the purchases, expected to close in September, would give it an expanded portfolio of rapid diagnostic capabilities in critical care.
Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.
The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.
The anatomic pathology lab said it had assets of between $1 million and $10 million, and liabilities of between $50 million and $100 million.